Archive
1250 articles, sorted by publication time.
N-acetylcysteine did not restore the deleted genes, but instead activated an alternative growth and antioxidant network, improving neural connectivity and cognitive performance in mice; whether this “detour” can lead to clinical applications remains a long way off.
A study of 217 people found that the tuberculosis antigen ESAT-6 in blood can distinguish active disease, latent infection, and other lung diseases. If prospective trials reproduce the results, it could accelerate triage when sputum is difficult to obtain, but it cannot yet replace culture confirmation and drug-resistance testing.
For patients with advanced non-small cell lung cancer whose disease continued to worsen after treatment with a ROS1 inhibitor, Jideytro shrank tumors in 44% of patients in a single-arm trial. This approval, completed ahead of schedule, fills a later-line treatment need, but comparative efficacy and long-term safety still require further evidence.
Of 285 viral genomes designed by a genomic language model, 16 formed bacteriophages capable of infecting Escherichia coli in the laboratory; the findings expand the design space for phage therapy but also show that safety governance must keep pace with the ability to generate entire genomes.
A new benchmark encompassing 1,609 samples backed by experimental and structural evidence shows that general-purpose large language models can capture broad epitope signals but struggle to reliably connect specific antibodies, amino acid positions, and immune escape.
The study examined C3 in the blood separately from C3 produced by the tumor stroma itself, finding that the latter can prevent immunosuppressive cells from entering; however, translating this mechanism into a treatment remains at the stage of studies in mice and patient samples.
mRNA-1469 has begun first-in-human testing in Canada against Bundibugyo ebolavirus, for which no vaccine is currently approved. The Phase 1 trial of approximately 80 people will initially examine safety and immune responses, with proof of protection still some way off.
DIAG723 aims to reactivate dysregulated angiogenic signaling, addressing recurrent nosebleeds, anemia, and arteriovenous malformations at the level of disease mechanism; however, dosing the first patient marks only the beginning of clinical validation, and its safety and efficacy in humans remain unknown.
Two single-patient trials used personalized antisense oligonucleotides to selectively suppress disease-causing SCN2A gene transcripts. After more than two years of treatment, both boys showed improvements in seizures and developmental abilities, but whether the benefits will persist and whether safety will withstand longer-term scrutiny remain to be determined through follow-up.
Two blood tests centered on p-tau217 identified brain amyloid with 90% accuracy in 39 adults with Down syndrome. The findings offer a starting point for lower-burden screening and clinical trial recruitment, but population-specific thresholds still require validation in larger studies.
Cretostimogene produced durable responses in patients with high-risk bladder cancer after BCG treatment failure, with no treatment-related adverse events of grade 3 or higher; however, the study had no control group, so it cannot yet establish whether the therapy is superior to other bladder-preserving treatments.
mRNA-4200 uses a single formulation to encode seven antigens shared across tumors, seeking to trigger a broader T-cell attack; the first-phase trial will initially address safety and immune response, rather than demonstrate efficacy.